These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38444824)

  • 21. Efficacy and Safety of Single-Pill Combination of Rosuvastatin and Ezetimibe in Chinese Patients with Primary Hypercholesterolemia Inadequately Controlled by Statin Treatment (ROZEL): A Randomized, Double-Blind, Double Dummy, Active-Controlled Phase 3 Clinical Trial.
    Su Q; Liu Y; Zhang G; Xu L; Wang M; Mei S; Garon G; Wu Y; Lv Q; Ma C
    Adv Ther; 2023 Dec; 40(12):5285-5299. PubMed ID: 37770770
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of high-dose rifampicin in the management of tuberculosis meningitis: Systematic review and meta-analysis.
    Charlie L; Abay SM; Tesfaye A; Mlera RN; Mwango S; Goretti M
    Int J Mycobacteriol; 2021; 10(3):312-319. PubMed ID: 34494572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improvement cues of lesion absorption using the adjuvant therapy of traditional Chinese medicine Qinbudan tablet for retreatment pulmonary tuberculosis with standard anti-tuberculosis regimen.
    Zhang SY; Fu JY; Guo XY; Wu DZ; Zhang T; Li C; Qiu L; Shao CR; Xiao HP; Chu NH; Deng QY; Zhang X; Yan XF; Wang ZL; Zhang ZJ; Jiang X; Zheng YJ; Zheng PY; Zhang HY; Lu ZH
    Infect Dis Poverty; 2020 May; 9(1):50. PubMed ID: 32381098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decreased Dolutegravir and Efavirenz Concentrations With Preserved Virological Suppression in Patients With Tuberculosis and Human Immunodeficiency Virus Receiving High-Dose Rifampicin.
    Sekaggya-Wiltshire C; Nabisere R; Musaazi J; Otaalo B; Aber F; Alinaitwe L; Nampala J; Najjemba L; Buzibye A; Omali D; Gausi K; Kengo A; Lamorde M; Aarnoutse R; Denti P; Dooley KE; Sloan DJ
    Clin Infect Dis; 2023 Feb; 76(3):e910-e919. PubMed ID: 35861296
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of delayed culture conversion among Ugandan patients.
    Atwine D; Orikiriza P; Taremwa I; Ayebare A; Logoose S; Mwanga-Amumpaire J; Jindani A; Bonnet M
    BMC Infect Dis; 2017 Apr; 17(1):299. PubMed ID: 28438118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of high-dose rifampicin on efavirenz pharmacokinetics: drug-drug interaction randomized trial.
    Atwine D; Baudin E; Gelé T; Muyindike W; Mworozi K; Kyohairwe R; Kananura K; Orikiriza P; Nyehangane D; K T Nanjebe D; Furlan V; Verstuyft C; Barrail-Tran A; Taburet AM; Bonnet M;
    J Antimicrob Chemother; 2020 May; 75(5):1250-1258. PubMed ID: 31999314
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis.
    Dierig A; Hoelscher M; Schultz S; Hoffmann L; Jarchow-MacDonald A; Svensson EM; Te Brake L; Aarnoutse R; Boeree M; McHugh TD; Wildner LM; Gong X; Phillips P; Minja LT; Ntinginya N; Mpagama S; Liyoyo A; Wallis RS; Sebe M; Mhimbira FA; Mbeya B; Rassool M; Geiter L; Cho YL; Heinrich N
    Trials; 2023 Jun; 24(1):382. PubMed ID: 37280643
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Salmonella isolation with Rappaport's enrichment medium of different compositions.
    Vassiliadis P; Trichopoulos D; Papadakis J; Kalapothaki V; Zavitsanos X; Serie C
    Zentralbl Bakteriol Mikrobiol Hyg B; 1981; 173(5):382-9. PubMed ID: 7282167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis.
    Berry C; du Cros P; Fielding K; Gajewski S; Kazounis E; McHugh TD; Merle C; Motta I; Moore DAJ; Nyang'wa BT
    Trials; 2022 Jun; 23(1):484. PubMed ID: 35698158
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials.
    Campbell JR; Trajman A; Cook VJ; Johnston JC; Adjobimey M; Ruslami R; Eisenbeis L; Fregonese F; Valiquette C; Benedetti A; Menzies D
    Lancet Infect Dis; 2020 Mar; 20(3):318-329. PubMed ID: 31866327
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment shortening of drug-sensitive pulmonary tuberculosis using high-dose rifampicin for 3 months after culture conversion (Hi-DoRi-3): a study protocol for an open-label randomized clinical trial.
    Kwak N; Jeon D; Park Y; Kang YA; Kim KJ; Kim YR; Kwon BS; Kwon YS; Kim HJ; Lee JH; Lee JY; Lee JK; Mok J; Cheon M; Park J; Hahn S; Yim JJ
    Trials; 2022 Aug; 23(1):666. PubMed ID: 35978342
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fluoroquinolones for treating tuberculosis (presumed drug-sensitive).
    Ziganshina LE; Titarenko AF; Davies GR
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD004795. PubMed ID: 23744519
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP).
    Ekqvist D; Bornefall A; Augustinsson D; Sönnerbrandt M; Nordvall MJ; Fredrikson M; Carlsson B; Sandstedt M; Simonsson USH; Alffenaar JC; Paues J; Niward K
    BMJ Open; 2022 Mar; 12(3):e054788. PubMed ID: 35273049
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose, short-duration versus standard rifampicin for tuberculosis preventive treatment: a partially blinded, three-arm, non-inferiority, randomised, controlled trial.
    Ruslami R; Fregonese F; Apriani L; Barss L; Bedingfield N; Chiang V; Cook VJ; Fisher D; Flores E; Fox GJ; Johnston J; Lim RK; Long R; Paulsen C; Nguyen TA; Nhung NV; Gibson D; Valiquette C; Benedetti A; Menzies D
    Lancet Respir Med; 2024 Jun; 12(6):433-443. PubMed ID: 38552659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
    [TBL] [Abstract][Full Text] [Related]  

  • 36. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Standard versus high dose of rifampicin in the treatment of pulmonary tuberculosis: a systematic review and meta-analysis.
    Onorato L; Gentile V; Russo A; Di Caprio G; Alessio L; Chiodini P; Coppola N
    Clin Microbiol Infect; 2021 Jun; 27(6):830-837. PubMed ID: 33813119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Six-month therapy for abdominal tuberculosis.
    Jullien S; Jain S; Ryan H; Ahuja V
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012163. PubMed ID: 27801499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized Trial of Metformin With Anti-Tuberculosis Drugs for Early Sputum Conversion in Adults With Pulmonary Tuberculosis.
    Padmapriydarsini C; Mamulwar M; Mohan A; Shanmugam P; Gomathy NS; Mane A; Singh UB; Pavankumar N; Kadam A; Kumar H; Suresh C; Reddy D; Devi P; Ramesh PM; Sekar L; Jawahar S; Shandil RK; Singh M; Menon J; Guleria R
    Clin Infect Dis; 2022 Aug; 75(3):425-434. PubMed ID: 34849651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.